如何治疗需要降细胞治疗的低危真性红细胞增多症患者
真性红细胞增多症(PV)是一种慢性血液系统恶性肿瘤,既往治疗重点仅针对血栓高危患者。本文基于低危PV并非无风险、部分治疗可能降低向骨髓纤维化转化风险及分子监测可识别疾病状态改善等认识,描述触发低危PV患者使用降细胞治疗的临床情境、具体降细胞药物的选择方法及有效监测治疗的方式。
要点
- 低危PV并非无风险,部分患者需考虑降细胞治疗。
- 选择降细胞药物需结合患者具体情况及治疗目标。
- 分子监测可能识别疾病状态改善并转化为总生存改善。
核心结论
- 低危PV并非无风险,部分患者可从更密集治疗中获益。
- 部分治疗可能降低向骨髓纤维化转化的风险。
- 分子监测可能识别疾病状态改善并转化为总生存改善。
研究设计与样本
- 本文为叙述性综述,基于作者经验与文献证据描述低危PV患者降细胞治疗的临床情境、药物选择及监测方法。
主要发现
- 低危PV并非无风险,需识别可从更密集治疗中获益的患者。
- 有数据显示部分治疗可能降低向骨髓纤维化转化的风险。
- 新兴证据提示分子监测可能识别疾病状态改善并转化为总生存改善。
临床怎么用
- 作者描述了触发低危PV患者使用降细胞治疗的临床情境。
- 作者描述了选择具体降细胞药物的方法。
- 作者描述了如何有效监测治疗。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Polycythemia vera (PV) was first described by Louis Henri Vaquez in 1892. It is a chronic hematological malignancy that affects both older and young patients. Perhaps because of lack of a curative treatment and the perceived toxicities of prior therapies, our focus in the past was to intensify treatment only for patients at higher risk of thrombosis. Recent triggers to challenge this approach include the following: a recognition that low-risk PV is not "no risk," our ability to better recognize patients who would benefit from more intensive therapy from the perspective of thrombosis, and data showing that some treatments may reduce risk of transformation to myelofibrosis. Furthermore, there is emergent evidence that molecular monitoring may identify an improvement in disease state translating to improved overall survival. Here, we describe clinical situations that would trigger the use of cytoreductive treatment for patients with low-risk PV as well as our approach to choosing a specific cytoreductive agent and how to effectively monitor treatment.
引用
- McMullin MF, Harrison CN. How I treat patients with low-risk polycythemia vera who require cytoreduction. Blood. 2025. PMID: 38848538. doi:10.1182/blood.2023022418
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。